Literature DB >> 22699216

[Pulmonary emergencies in connective tissues disorders and vasculitides].

J O Schröder1, R A Zeuner, B Bewig, M Both.   

Abstract

Pulmonary emergencies in rheumatic diseases are rare, potentially life-threatening conditions that occur either as a manifestation of the disease itself or as an adverse event of immunosuppressive treatment. Diffuse alveolar hemorrhage, tracheal stenosis, acute pneumonitis and drug-induced lung injury belong to this category. The management of these emergencies requires intensive cooperation between rheumatology and pulmonology. The latter contributes its experience in the care of related conditions, specific endoscopic techniques and local interventions as well as the indispensable and life-supporting forms of assisted ventilation. The present article summarizes the current knowledge on diagnostic and therapeutic procedures including the newly available B-cell directed treatments.

Entities:  

Mesh:

Year:  2012        PMID: 22699216     DOI: 10.1007/s00393-011-0916-1

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  29 in total

1.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Subglottic and tracheal stenosis associated with multifocal fibrosclerosis.

Authors:  Ahmad A Orabi; Ajay Negam; Charles Bulman
Journal:  Acta Otolaryngol       Date:  2007-06       Impact factor: 1.494

Review 3.  Wegener's granulomatosis: current trends in diagnosis and management.

Authors:  Vanessa R Erickson; Peter H Hwang
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2007-06       Impact factor: 2.064

Review 4.  Antiphospholipid syndrome: frequency, main causes and risk factors of mortality.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2010-04-13       Impact factor: 20.543

Review 5.  Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis.

Authors:  Alina Casian; David Jayne
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

6.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

7.  Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis.

Authors:  R A Matthay; M I Schwarz; T L Petty; R E Stanford; R C Gupta; S A Sahn; J C Steigerwald
Journal:  Medicine (Baltimore)       Date:  1975-09       Impact factor: 1.889

Review 8.  Lung toxicity associated with cyclophosphamide use. Two distinct patterns.

Authors:  S W Malik; J L Myers; R A DeRemee; U Specks
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

9.  Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis.

Authors:  C A Langford; M C Sneller; C W Hallahan; G S Hoffman; W A Kammerer; C Talar-Williams; A S Fauci; R S Lebovics
Journal:  Arthritis Rheum       Date:  1996-10

10.  Isolated pulmonary capillaritis and diffuse alveolar hemorrhage in rheumatoid arthritis and mixed connective tissue disease.

Authors:  M I Schwarz; M R Zamora; T N Hodges; E D Chan; R P Bowler; R M Tuder
Journal:  Chest       Date:  1998-06       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.